# A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

> **NCT02492763** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 176 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** MK-8521
- **DRUG:** Placebo
- **DRUG:** Liraglutide
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02492763
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-27
- **Primary completion:** 2017-04-18
- **Final completion:** 2017-04-18
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2018-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02492763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02492763, "A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02492763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*